



Recent Advances in Malaria Vaccine Development

Guest Editors:

Dr. Ahmad R. Shakri

Division of Infectious Disease and
International Medicine,
Department of Internal Medicine,
University of South Florida, 3720
Spectrum Blvd, Tampa, FL 33612,
USA

Dr. Dipak Raj

Division of Infectious Disease and
International Medicine,
Department of Internal Medicine,
University of South Florida, 3720
Spectrum Blvd., Tampa, FL
33612, USA

Deadline for manuscript
submissions:

15 October 2024

Message from the Guest Editors

Infections caused by malaria parasites are a major burden to global human health. As one of the deadliest parasitic diseases, malaria continues to cause significant morbidity and mortality, with an estimated 241 million clinical cases and over 0.6 million deaths reported in 2021*.

Increasing resistance to currently deployed anti-malarial drugs continues to be a major concern in the fight against the disease. While *Plasmodium falciparum* causes the majority of malaria-related mortality, safe and efficacious vaccines for both *P. falciparum* and *P. vivax* are needed as cost-effective tools for the prevention and elimination of malaria globally. Importantly, in addition to the world's first and only vaccine recommended for falciparum malaria prevention in children (RTS, S/AS01), multiple vaccines against malaria that provide high efficacy and meet the malaria vaccine supply capacity will be necessary.

This Special Issue of *Vaccines* aims to showcase new developments in both falciparum and vivax malaria vaccines.

We look forward to your contributions, including original research and reviews, for this Special Issue.

**WHO World Malaria Report 2022*





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com